O.S. Michael, J.A. Badejo, M.O. Adeoye and C.O. Falade

Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria.


The COVID-19 pandemic has spread to many malaria endemic countries in sub Saharan Africa. There is little or no experience on how the impact of policies put in place to curtail further spread of the pandemic will affect the epidemiology of malaria during the malaria season. The objective of this write-up is to put in perspective, the need to ensure effective malaria control in the midst of the COVID-19 crises. Proper integration of the COVID-19 safety and treatment guidelines with malaria control policies and effective diagnosis in malaria endemic countries in sub Saharan Africa are important in mitigating morbidity and mortality rates which may rise if malaria cases are neglected due to the current burden of the COVID-19 pandemic.


Dr. O.S. Michael
Dept. of Pharmacology and Therapeutics
College of Medicine
University of Ibadan,


In 2018, 228 million cases of malaria occurred worldwide, 213 million of these cases (93%) occurred in the African region.1 Six countries accounted for more than half of all malaria cases; Nigeria (25%), the Democratic Republic of the Congo (12%), Uganda (5%), and Cote d’Ivore, Mozambique, and Niger 4% each.1 Effective management of the disease depends on accurate diagnosis followed by prompt and effective treatment. In Nigeria, heavy rains mark the malaria season.2 There is a need to plan for the integration of malaria control on the background of concerted efforts to slow down the spread of COVID-19. Improper integration of control measures may result in the loss of recent gains in the control of malaria in malaria endemic countries. Practices that may place malaria infected individuals (especially pregnant women and children) at a high risk of increased morbidity and mortality in the COVID-19 pandemic include stigmatization of COVID-19 infected people, improper allocation of scarce medical resources, improper use and interpretation of antigen-based malaria rapid diagnosis test kits, prioritizing testing for COVID-19 over malaria in febrile individuals, use of routine rather than expert microscopy, and malaria cases presenting with cough.

Stigmatization of COVID-19 infected people: Data from those infected with COVID-19 shows that fever and cough were the dominant symptoms with a case fatality ranging from 1 to 3%. 3 It is yet undetermined if a persistent chronic infection can occur. Majority of those infected with COVID-19 remain asymptomatic and recover. It is prudent to consider that stigmatization of people infected with COVID-19 may result in people with febrile illnesses avoiding hospitals for fear of being seen by others as being infected with COVID-19. In addition, the fear of coming in contact with COVID-19 cases may also lead to the avoidance of hospital care. It is known that the longer the period between the onset of malaria symptoms and the commencement of effective therapy, the higher the chances of mortality from the disease.4-5 Without proper integration of malaria and COVID-19 management with targeted interventions to prevent stigmatization of those diagnosed with COVID-19, mortality from malaria in endemic countries may rise. Therefore, stigmatization of COVID-19 patients should be prevented.

Improper allocation of scarce medical resources: Globally in 2019 there was an estimated 229 million malaria cases with 409,000 deaths.6 The economic burden of malaria in resource- constrained countries is substantial.7-9 With the current intense focus on the COVID-19 pandemic, the probability of an imbalance between supply and demand for medical resources is high.10-11 In addition, shortage of antimalarial drugs during the malaria seasons, especially in resource constrained countries of sub-Saharan Africa may pose a challenge to the control of malaria. Scarcity may occur due to reduced focus on malaria. Also, fear-driven use of antimalarial drugs in the treatment of COVID19 symptoms may weaken appropriate management of malaria.12-14 Initial treatment of fever related with COVID-19 during the ongoing pandemic may also result in a rise in malaria morbidity and mortality. There is a need for plans towards tackling these potential challenges early to avoid their impact on malaria control in endemic countries. While the attention of a majority of tertiary healthcare centers is presently focused on COVID-19, malaria care may have to be redirected to the primary and secondary health care centers. At these centers, small teams trained in the rapid recognition of potential cases of COVID-19 will have to be deployed in a properly interpreted malaria and COVD-19 response agenda.

Use of Antigen based Malaria Rapid Diagnosis Test Kits: The high infectivity of COVID-19 is likely to shift the diagnosis of malaria to the use malaria rapid diagnosis tests (mRDT) in order to avoid having to prepare blood smears for malaria microscopy. It is worth considering that, during the ongoing pandemic, the combination of PfHRP2 and Pf-pLDH (Combo) test kits should be used in order to minimize the shortcomings of PfHRP2 RDTs. 15 Prolonged persistence of pfHRP2 antigen is common in those with successful clearance of the malaria parasite. This can pose a great danger to health workers. A false positive malaria result in a COVID-19 positive individual may result in the relaxation of personal preventive measures and a high risk of transmission of infection to care givers.16 There may also be a need to consider the use of validated PCR-based methods of diagnosis of malaria which can be integrated with the PCR-based diagnosis of COVID-19.